Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Third Rock Ventures funds reported a small sale of Rapport Therapeutics stock. Third Rock Ventures V, L.P. sold 18,572 shares of Rapport Therapeutics, Inc. common stock on May 26, 2026 in open-market transactions at a weighted average price of $40.047 per share, under a pre-arranged Rule 10b5-1 trading plan dated November 21, 2025.
After the sale, Third Rock Ventures V, L.P. directly held 6,280,525 shares of common stock. A related fund, Third Rock Ventures VI, L.P., is reported with 969,218 shares held indirectly, reflecting a continuing, sizeable ownership position across these affiliated investment entities.
Third Rock Ventures V, L.P. reported dispositions of Common Stock of RAPP. The excerpt lists secondary sales on 04/17/2026 of 426,005 shares for $17,175,115.78, on 05/07/2026 of 271,495 shares for $47,826,929.00, on 05/08/2026 of 5,018 shares for $202,254.50, and on 05/11/2026 of 133,618 shares for $5,378,124.50. The filing lists an original issuance on 02/21/2023 of 2,803,200 shares (cash).
Rapport Therapeutics, Inc. ownership update: Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 2,957,521 shares of common stock (representing 6.19% of the class).
The percentage is calculated using 47,792,943 shares outstanding as of March 2, 2026. This filing is Amendment No. 4 to the prior Schedule 13G statement.
Third Rock Ventures V, L.P. reported an open-market sale of 133,618 shares of Rapport Therapeutics, Inc. common stock on May 11, 2026 at a weighted average price of $40.244 per share. The sale occurred in multiple trades between $40.00 and $40.665 per share under a previously adopted Rule 10b5-1 trading plan.
After this transaction, Third Rock Ventures V directly held 6,299,097 shares of Rapport Therapeutics common stock. A related fund, Third Rock Ventures VI, L.P., is reported as holding an additional 969,218 shares indirectly, with the general partner entities disclaiming beneficial ownership except to the extent of any pecuniary interest.
Rapport Therapeutics, Inc. significant shareholder entities affiliated with Third Rock Ventures reported open-market sales of common stock. Third Rock Ventures V, L.P. sold 271,495 shares on May 7, 2026 at a weighted average price of $40.1210 per share and 5,018 shares on May 8, 2026 at a weighted average price of $40.3060 per share, totaling 276,513 shares sold. These transactions were executed under a previously adopted Rule 10b5-1 trading plan. After the sales, the reporting entities hold 6,432,715 shares directly through Third Rock Ventures V, L.P. and 969,218 shares indirectly through Third Rock Ventures VI, L.P., indicating a large remaining position.
Third Rock Ventures V, LP reported sales of Common Stock in transactions reported on Form 144. The excerpt lists three dispositions: 426,005 shares for $17,175,115.78 on 04/17/2026, 271,495 shares for $47,826,929.00 on 05/07/2026, and 5,018 shares for $202,254.50 on 05/08/2026. The record also shows an original issuance of 2,803,200 shares on 02/21/2023.
Third Rock Ventures V, L.P. reported Rule 144 notices covering recent resale activity in the issuer's common stock. The filing lists sales of 426,005 shares on 04/17/2026 for $17,175,115.78 and 271,495 shares on 05/07/2026 for $47,826,929.00. The record also shows an original issuance of 2,803,200 shares on 02/21/2023 to the issuer for cash.
Third Rock Ventures V, LP reported proposed sale of 426,005 shares of Common stock of RAPP. The filing lists a sale date of 04/17/2026 and a dollar figure of $17,175,115.78 associated with that entry. The notice names Raymond James & Associates as the broker and references an earlier original issuance of 2,803,200 shares on 02/21/2023.
Rapport Therapeutics reported its first collaboration revenue and a narrower quarterly loss while accelerating its neurology pipeline. For the three months ended March 31, 2026, collaboration revenue was $20,000 (thousand) driven by a new regional licensing deal, compared with none a year earlier. Research and development expenses rose to $32,716 thousand and selling, general and administrative costs to $11,499 thousand, reflecting expanded clinical activity and public-company infrastructure. Net loss improved to $19,857 thousand, or $0.42 per share, versus a $24,063 thousand loss, or $0.68 per share, in the prior-year quarter. Cash, cash equivalents and short-term investments totaled $476,782 thousand as of March 31, 2026, supported by a $269,400 thousand follow-on equity offering completed in 2025, giving the company resources to fund late-stage trials of lead candidate RAP-219 for focal onset seizures and bipolar mania and to advance earlier programs.
Rapport Therapeutics reported first quarter 2026 results and highlighted major progress for its lead candidate RAP-219. Collaboration revenue was $20.0 million, driven by a new license agreement with Tenacia Biotechnology, while net loss narrowed to $19.9 million from $24.1 million a year earlier.
R&D expenses rose to $32.7 million and G&A to $11.5 million as the pipeline expanded. The company ended the quarter with $476.8 million in cash, cash equivalents and short-term investments, which it expects will fund operations into the second half of 2029.
Phase 2a follow-up data in focal onset seizures showed sustained effects, including a 90% median reduction in clinical seizures over baseline in weeks 9–12. A Phase 3 program in focal onset seizures is on track to start in the second quarter of 2026, and Phase 2 bipolar mania topline data are now expected in the fourth quarter of 2026, earlier than prior guidance.